Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution

The optimal treatment strategy for synovial sarcoma (SS) is subject to debate, and different strategies have been used for pediatric and adult patients. The current retrospective analysis examined a large group of patients of all ages who were treated at a single institution over a 30‐year period.

[1]  M. Burt,et al.  Tendosynovial sarcoma. Clinicopathologic features, treatment, and prognosis , 1992, Cancer.

[2]  C. Fisher,et al.  Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Sylvester,et al.  Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data , 1997 .

[4]  A. Pappo,et al.  Synovial sarcoma in children and adolescents: the St Jude Children's Research Hospital experience. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Sozzi,et al.  Analysis of SYT-SSX Fusion Transcripts and bcl-2 Expression and Phosphorylation Status in Synovial Sarcoma , 2000, Laboratory Investigation.

[6]  J. Edmonson,et al.  Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  V. Bramwell Adjuvant chemotherapy for adult soft tissue sarcoma: Is there a standard of care? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Munsell,et al.  Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M Bonetti,et al.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Gehan,et al.  The intergroup rhabdomyosarcoma study‐I. A final report , 1988, Cancer.

[11]  W. Enneking,et al.  A System for the Surgical Staging of Musculoskeletal Sarcoma , 1980, Clinical orthopaedics and related research.

[12]  S. Todo,et al.  [TNM classification--pediatric tumors]. , 1998, Gan to kagaku ryoho. Cancer & chemotherapy.

[13]  S. Spunt,et al.  Soft tissue sarcomas of childhood. , 2004, Cancer treatment reviews.

[14]  G. Rosen,et al.  Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease , 1993, Cancer.

[15]  A. Santoro,et al.  Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Davis,et al.  A comparison of staging systems for localized extremity soft tissue sarcoma , 2000, Cancer.

[17]  H. Gadner,et al.  Synovial sarcoma of childhood and adolescence. Report of the german CWS‐81 study , 1993, Cancer.

[18]  J. Crowley,et al.  An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Crowther Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data , 1997, The Lancet.

[20]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[21]  M. Berretta,et al.  Ifosfamide in the Adjuvant Therapy of Soft Tissue Sarcomas , 2003, Oncology.

[22]  P. Casali,et al.  Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor β Tyrosine Kinase Receptors in Synovial Sarcoma , 2004, Clinical Cancer Research.

[23]  A. Pappo,et al.  Rhabdomyosarcoma and other soft tissue sarcomas of childhood. , 1994, Current opinion in oncology.

[24]  L. Kindblom,et al.  Synovial sarcoma , 1999 .

[25]  G. Rosen,et al.  Synovial sarcoma. Uniform response of metastases to high dose ifosfamide , 1994, Cancer.

[26]  F. Collin,et al.  Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Galimberti,et al.  Synovial sarcoma: report of a series of 25 consecutive children from a single institution. , 1999, Medical and pediatric oncology.

[28]  C. Antonescu,et al.  Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Mariani,et al.  SYT-SSX fusion genes and prognosis in synovial sarcoma , 2001, British Journal of Cancer.